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Abstract
Background: High-throughput gene expression profiling technologies generating a wealth of data, are increasingly used for
characterization of tumor biopsies for clinical trials. By applying machine learning algorithms to such clinically documented
data sets, one hopes to improve tumor diagnosis, prognosis, as well as prediction of treatment response. However, the
limited number of patients enrolled in a single trial study limits the power of machine learning approaches due to over-
fitting. One could partially overcome this limitation by merging data from different studies. Nevertheless, such data sets
differ from each other with regard to technical biases, patient selection criteria and follow-up treatment. It is therefore not
clear at all whether the advantage of increased sample size outweighs the disadvantage of higher heterogeneity of merged
data sets. Here, we present a systematic study to answer this question specifically for breast cancer data sets. We use
survival prediction based on Cox regression as an assay to measure the added value of merged data sets.
Results: Using time-dependent Receiver Operating Characteristic-Area Under the Curve (ROC-AUC) and hazard ratio as
performance measures, we see in overall no significant improvement or deterioration of survival prediction with merged
data sets as compared to individual data sets. This apparently was due to the fact that a few genes with strong prognostic
power were not available on all microarray platforms and thus were not retained in the merged data sets. Surprisingly, we
found that the overall best performance was achieved with a single-gene predictor consisting of CYB5D1.
Conclusions: Merging did not deteriorate performance on average despite (a) The diversity of microarray platforms used.
(b) The heterogeneity of patients cohorts. (c) The heterogeneity of breast cancer disease. (d) Substantial variation of time to
death or relapse. (e) The reduced number of genes in the merged data sets. Predictors derived from the merged data sets
were more robust, consistent and reproducible across microarray platforms. Moreover, merging data sets from different
studies helps to better understand the biases of individual studies and can lead to the identification of strong survival
factors like CYB5D1 expression.
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Introduction
Microarraygeneexpressiondata havebeen integratedtoincrease
statistical power. Increasing sample size is a bottleneck in DNA
microarray-based gene expression studies as microarray experi-
ments are time consuming, expensive, noisy and limited to the
number of biological samples (particularly, cancer patients). To
circumvent this problem, microarray gene expression data sets
addressing the same or similar biological questions have been
analyzed jointly either by so-called meta analysis [1–5], which
means integration at the level of results derived separately from
individual data sets, or by data merging[6–16]. Butdata integration
prior to analysis potentially faces problems related to reproducibility
as different microarray platforms use different probes for the same
genes and return expression values on different numerical scales.
Some studies combined data sets generated with the same chip
[6–8,10], or with the same technology platform but different
chips [9,11–14,17,17–19], or with heterogeneous microarray
technologies [15,16,20,21]. The rationale behind combining
data sets generated only from the same chip or platform was to
avoid the cross-platform bias. As it is difficult to measure absolute
mRNA concentrations by hybridization-based expression pro-
filing techniques, one would expect gene-specific systematic
differences between expression values obtained with different
probes. Systematic differences between published data sets may
also result from different pre-processing steps applied by the
authors. For instance, expression levels are sometimes expressed
as absolute values, sometimes as log ratios with respect to a
reference sample. To avoid bias resulting from preprocessing,
Reyal et al [6] restricted their studies to data sets generated with
the same chip (Affymetrix HG-U133A) for which raw data were
available, and re-processed all data sets prior to merging. Other
studies used homogeneous (same technology) [8,9,11–13] or
heterogeneous [15,16,20] data sets, as pre-normalized in the
original studies, and applied a so-called data integration method
prior to data fusion.
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values for the same gene onto comparable scales. Perhaps the
simplest way to approximately achieve this goal is Z-score
normalization [22]. More advanced methods attempt to match
data-set specific parameters of the expression value distribu-
tions between input sets. Data integration methods that have
been used in similar studies before include: Distance Weighted
Discrimination (DWD) [23,11,14–16,24], Combatting Batch
effects (ComBat) [25,12], disTran [26], Median Rank Score
(MRS) [20], Quantile Discretizing (QD) [20] or Z-score trans-
formation [22].
Another necessary processing step in data merging consists of
mapping microarray features to a catalogue of standard gene
names. This in turn will result in the definition of the subset of
common genes to be retained in the merged data set. Here, the
term microarray feature refers to a single hybridization probe, or
a set of probes, for which the platform returns a single expression
value. Commercially available microarrays often contain multi-
ple features for the same gene. What makes the merging of data
sets non-trivial is that different platforms refer to the same genes
by different names. Note further that for the reasons outlined
above, merging of data sets usually leads to a substantial
reduction in the number of genes considered for downstream
analysis. Important genes included in only a part of the input
data sets may be lost.
Some studies [10,15,17,20] used UniGene ID [27] to identify
common genes between different data sets whereas other studies
employed different databases such as RefSeq [28,17] or
Stanford Source database (http://source.stanford.edu) [14,16]
to match probes/probe sets to genes. Note further that some
research teams used directly probe/clone identifiers [14] or
probe set IDs [6–8,12,13] when merging only cDNA or
Affymetrix data set collections, respectively. The latter studies
might have preferred not collapsing features (Probe/probe set)
into genes in order to keep the same annotation as other studies
to validate the same features. An additional reason to keep
original feature IDs is to preserve a large number of features
rather than a a smaller number of genes to make biological/
statistical inferences. Sohala n dc o w o r k e r s[ 1 7 ]u s e db o t h
UniGene ID and RefSeq ID to make a comparison of common
genes. They concluded that using UniGene IDs achieved
slightly better results than using RefSeq IDs, with a small
m a r g i n .I nt h i ss t u d y ,w eu s e do u ro w nr e s o u r c eC l e a n E x[ 2 9 ]
for mapping microarray features to gene names, a database
specifically developed for this purpose.
While some research projects merged the gene expression
values in their original continuous representation [6,11,12,14,15],
some other studies combined the ranks of gene expression values
[7–9,20,30] which are independent from normalization. In these
studies, ranking was used to predict a categorical outcome. Note
that ranking methods replace the continuous values by discrete
integer values which influences the choice of data integr-
ation method. While DWD and ComBat preserve the original
representation of data, MRS, QD and disTran transform the
data representation into discrete values.
In previous studies, merging data sets was applied to derive a
robust gene signature prognostic of survival time (Overall Survival
(OS) [11], or prognostic of survival outcome discretized into two
[6–10,13,20], or more categorical values [12,14–16,20,24], or
diagnostic of tumor subtypes [14–16,24], or predictive of
treatment response [12]. The gene signatures were built by a
supervised machine learning algorithm like Support Vector
Machines (SVM) [7,10,13,20–22] or unsupervised classification
methods like clustering [14–16,24] or statistical method such as
Cox regression model [11] and likelihood ratio test [9]. Such gene
signatures consist of a list of genes, usually associated with weights
that are used to compute a predictive score.
In previous tests, the potential advantage of data merging was
evaluated by means of a quantitative rate of correct classification
or validation of previous results. Note however that different
studies used different performance measures (sensitivity, specificity,
Area Under the Curve (AUC), percentage of concordance in
classification, etc) to this end.
Gene signatures are also evaluated in terms of ‘‘robustness’’ and
‘‘reproducibility’’. Robustness is related to the sample size of the
training set from which a gene signature is built and the size of the
testing set on which it is validated. A predictor generated from a
small training set could have a high prediction accuracy on the
training set but may lose generalization power when it is validated
on an independent testing set. Moreover, performance estimates
obtained with a small testing set have high statistical error, i.e. they
come with a large confidence interval. On the other hand,
reproducibility [31] means the convergence of results obtained
from replicate experiments, possibly carried out in different labs
and relying on different technologies. Reproducibility is assessed
by cross-data set validation, i.e. the evaluation of a gene signature
derived from one data set, with a testing set originating from
another study.
In this work, we analyzed the potential benefits of merging
data sets for prognostic application in breast cancer diagnosis.
Contrary to related work, we did not discretize the clinical follow-
up information into good and poor outcome classes, a practice
which results in loss of information. Instead, we directly used
censored survival data to derive a gene signature that allows for
the computation of a risk score from a patients expression profile.
The risk score was based on the Cox proportional hazard model,
and expected to be inversely related to the time to death or
relapse.
The basic design of our study is as follows (Figure 1). We used
eight breast cancer microarray data sets from eight different
studies (Table 1). Each set had clinical follow-up information in
form of censored time to event data, the event being either
‘‘overall survival’’ (OS) or ‘‘relapse-free survival’’ (RFS) or both.
The goal was to extract a gene signature from a training set that
can be used to predict disease outcome for patients in the testing
set. The gene signature (predictor) we used consisted of a set of
genes plus corresponding Cox coefficients derived by univariate
fitting of the expression values to the survival data on the training
set. Gene signatures were built from the individual or merged data
sets. The accuracy and robustness of prediction were evaluated by
10-fold cross-validation. Reproducibility as defined above was
analyzed by training a signature from one or several complete data
sets and testing its performance on complete independent
validation sets.
Data sets were merged in their original (continuous) numerical
representation using two different data integration methods: (i)
ComBat [25] and (ii) Z-score normalization. Two signature
performance measures were computed in each experiment: (i) time
dependent Receiver-Operator Characteristic Area Under the
Curve (ROC-AUC) and (ii) the hazard ratio (HR) of the predicted
risk scores relative to the survival data in the testing set. Note that
the latter required stratification of the testing set patients in a high
and low risk groups.
In total, we analyzed 1324 breast cancer samples from public
data sets generated with three microarray technologies (cDNA,
Agilent, Affymetrix). To the best of our knowledge, this study is the
largest one evaluating the potential benefits of data merging in a
quantitative OS/RFS patients risk prediction framework.
Survival Prediction & Merging
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Verification of Data Integration
To assess the removal of microarray bias effect across data sets,
Principal Component Analysis (PCA) and hierarchical clustering
wereappliedto the data setsafterthe applicationof data integration
methods.
The results of these tests are shown in Figure 2, Figure 3 and
Figure 4. In all figures, samples from the same source are
represented by the same color. Samples from different sources are
represented by different colors. In the heatmaps, green color of
pixels illustrates low expression level and red color depicts the high
expression level of the genes, respectively.
For the verification of data integration by PCA, the merged data
sets were projected on the planes defined by the first two principal
components (PCs). The purpose was to demonstrate intermixing of
samples from different sources. As can be seen, ComBat was
successful in removing dataset-specific biases (Figure 2, Figure 3)
since the samples of the merged data set integrated with ComBat
were better intermixed than the samples merged with Z-score
normalization.
The PCA results were confirmed by clustering. Figure 4 presents
the results for the datasets with OS and RFS events annotation,
respectively. The samples were grouped by data source when they
were normalized by Z-score normalization (Figure 4A, Figure 4C).
Here, genes are presented in rows and samples are organized in
columns. After the application of ComBat, the influence of data
sourceongroupingwassignificantlyreduced(Figure4B,Figure4D).
Assessment of Gene Signatures
Evaluation in 10-fold Cross Validation. The major goal of
our study was to assess the benefits of data merging with regard to
disease outcome prediction. To this end, we derived gene signatures
based on Cox regression from the individual and merged datasets as
described in the Methods section. The results of these tests can
be summarized as follows. For the data sets with OS endpoint
(Figure 5A, Figure 6A), the average AUC over 10-fold cross
validation (CV) remained comparable between the merged and
single data sets withinthelimitsofthe respective standard deviations
(ranging from 0.01 to 0.05). Although neither the prediction power
(AUC) nor the hazard ratio (HR) with the merged data sets
increased significantly, the HR of the merged data sets had a more
robust (shorter) asymptotic 95% confidence interval (CI).
We compared two data integration methods: (i) ComBat and (ii)
Z-score normalization as described under Methods. Based on PCA
and clustering results, we observed that ComBat was more efficient
in inter-mingling the samples. We therefore expected that ComBat
would outperform Z-score normalization. However,we noticed that
the two methods performed about equally well. The AUC values
generatedfromthemergeddatasetsbasedonthetwomethodswere
identical. The HR however is slightly higher for ComBat (ComBat:
Figure 1. The flowchart of this study.
doi:10.1371/journal.pone.0007431.g001
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Figure 6).
One possible explanation for this apparent contradiction would
be that the first two principle components and the clustering trees
obtained after data integration reflect biologically irrelevant
technical variance not related to data source. We tested this
hypothesis by fitting the first two principal components obtained
after the application of ComBat and Z-score normalization to the
merged survival data. We obtained the hazard ratios of 1.40 and
0.79 for PC1 and PC2, respectively, after Z-score normalization
Figure 2. Distribution of the merged breast cancer data sets with OS after the application of PCA. Color legend of data source: yellow:
Vijver, blue: GSE1992, pink: GSE1456, red: GSE3143, brown: GSE4335.
doi:10.1371/journal.pone.0007431.g002
Table 1. Survival breast cancer datasets with OS and RFS endpoints.
Data set Platform Pre-normalization Gene nb Sample size Ref. Treatment
Survival
outcome
GSE3143 Affymetrix, HG-U95A MAS5.0 8660 158 Bild 06 [55] Unknown OS
GSE1456A&B Affymetrix, HG-U133A&B MAS5.0, global mean 15848 159 Pawitan 05 [56] Adj. Chemotherapy (incl.
Tamoxifen)
OS, RFS
GSE4335 cDNA Scaling 12793 122 Sorlie 03 [57] Neoadj. Chemo/chemo
(Tamoxifen)-82 patients
OS, RFS
GSE1992 Agilent LOWESS 15528 170 Hu 06 [15] Treated OS, RFS
Vijver Agilent Scaling 13628 295 Van de Vijver 02 [36] Chemo/hormonal therapy
(90 patients)
OS, RFS
GSE2990 Affymetrix, HG-U133A RMA 12010 189 Sotiriou 06 [46] Tamoxifen (64 patients) RFS
GSE2034 Affymetrix, HG-U133A MAS5.0 12010 286 Wang 05 [38] None RFS
GSE4922A&B Affymetrix, HG-U133A&B MAS5.0, global mean 15848 289 Ivshina 06 [58] Systemic/endocrine therapy
(147 vs. 66 patients)
RFS
Merged OS Affymetrix, Agilent, cDNA 7049 849 OS
Merged RFS Affymetrix, Agilent, cDNA 9181 1324 RFS
Gene nb refers to the number of genes. MAS 5.0 refers to Affymetrix Microarray Suite version 5.0 and LOWESS stands for LOcally WEighted Scatter plot Smoothing and
RMA for Robust Microarray Analysis, respectively. Adj. stands for adjuvant and chemo for chemotherapy. Merged OS refers to merged data sets with Overall Survival
endpoint and Merged RFS refers to the merged data sets with Relapse Free Survival endpoint. The expression values of dual channel data were already log2-transformed.
Among the data sets generated by Affymetrix, the absolute intensity values of GSE3143, GSE2034 and GSE2990 were log2-transformed for this study as the rest of
Affymetrix data sets were already log2- transformed by the authors.
doi:10.1371/journal.pone.0007431.t001
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merged data sets (P-values 7.3-e01 and 3.7-e14). While these
values do not precisely confirm our hypothesis, they indicate that
the first two principal components capture the variance related to
survival about equally well in both cases.
We observed similar trends when looking at the distribution of
Estrogen Receptor positive (ER+) and Estrogen Receptor negative
(ER-) samples in the clustering diagrams. There we saw both after
the application of ComBat and Z-score normalization many small
clusters of ER- samples (the minority class) spread over the entire
range of the tree (data not shown). While these findings conciliate
the results from data integration verification with those from gene
signature evaluation, they also reveal the limited usefulness of the
data intermingling test, which in this case provides a misleading
picture of the variance retained after data integration.
Noting that the gene signatures built from subsets of GSE4335
or Vijver showed higher prediction accuracies in cross-validation
than the gene signature built from the merged data set, we
investigated how the performance could possibly be improved by
selective data integration. With regard to both OS and RFS
results, we made the following general observation: (i) The
prediction accuracy obtained with a signature from a merged
data set lies between the accuracies of the signatures derived from
the component data sets. (ii) There are marked differences in
performance of signatures from individual data sets, possibly
reflecting the quality of the data or the diversity of the analyzed
patient cohorts. Overall, these observations are in agreement with
results from similar tests where performance was measured by a
binary classification assay [7,20,30].
Taking into account this observation, the data sets with the
highest prediction accuracies were merged in different combina-
tions in the hope to improve the overall prognostic power of a
signaturebased on a merged dataset. Firstly, the data sets GSE4335
and Vijver were merged and adjusted by a data integration method
(ComBat or Z-score normalization), resulting in a predictor with an
average AUC of 0.73+/20.01, HR=4.8 (CI=4.19–5.50). Adding
the data set GSE1992 reduced the prognostic power by 0.01 only
(average AUC=0.72, HR=3.84, CI=3.17–4.65). Combining the
data sets GSE4335 and GSE1992 resulted in a mean AUC of 0.70
(+/20.02) and an HR of 3.35 (CI=2.55–4.30). The AUC obtained
from the combination of GSE4335 and GSE1992 is comparable to
the result obtained by combining GSE4335 and Vijver but the HR
decreased by 1 unit. Adding the Vijver data set to GSE4335 and
GSE1992 resulted in a similar prediction accuracy of mean AUC
0.72+/20.01 but a higher HR=4.53, CI=4.03–5.09. These
results show that the performance of the merged data set composed
of two data sets was as good as the merged data set composed of five
data sets. Interestingly, these pairs of data sets (GSE4335 and Vijver
or GSE4335 and GSE1992) were generated by different gene
expression profiling technologies, indicating that platform-specific
biaseswere not a majorobstacletodata merging. Importantly,these
results suggest that the potential added-value gained by including a
specific data set in a merged data set is predictable from its cross-
validated performance measured in isolation.
Taken all these together, however, the improvement seen with
selectively merged data sets is relatively modest as compared to the
prognostic power generated from the merged data sets composed
of all OS single data sets. Nevertheless, this improvement is
remarkable if one takes into account that the selectively merged
data set only contains about one-third (237) or half (410) as many
samples as the complete merged data set (849).
In the case of RFS (Figure 5B), the merged data sets adjusted by
ComBat and Z-score normalization outperformed the single data
set GSE2990 by 0.07 AUC. Compared to the other single data sets,
the results generated from the merged data sets remained equal or
lower by 0.00–0.06 AUC units. Here, the combination of the data
sets GSE4335 and GSE1992 had a better prediction accuracy with
a mean AUC of 0.68+/20.02 and an HR of 3.72 (CI=2.91–4.75)
Figure 3. Distribution of the merged breast cancer data sets with RFS after the application of PCA. Color legend of data source: yellow:
Vijver, blue: GSE1992, pink: GSE1456, grey: GSE2990, brown: GSE4335, black: GSE4922, green: GSE2034.
doi:10.1371/journal.pone.0007431.g003
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generated from the 1324-sample merged data sets. Adding the
Vijver data set resulted in a similar prediction accuracy with a mean
AUC of 0.66+/20.01 and HR=3.05 CI=2.24–4.05.
Comparing the performance results of the merged data sets, we
observe that none of the merged data sets was more successful in
prediction performance than the best individual data sets. Again
ComBat and Z-score integration produced similar results, with a
slight advantage of the latter method in this case.
To determine the significance and stability of the selected gene
signatures, we were then interested to investigate if the top 100-
ranked genes would still be selected if a P-value cut-off of 0.05 after
Bonferroni correction [32] was applied. We noticed that all the top
100-ranked genes derived from the merged and the Vijver data set
had a significantadjustedCoxP-value.Thiswas not the case for the
100-gene signatures built from any of the other single data sets.
The 1-gene signature derived from GSE4335 (see below) also
systematically had a significant adjusted Cox P-value. The adjusted
Figure 4. Heatmaps of the merged breast cancer data sets for all genes. (A) Z-score normalization with OS endpoint, (B) ComBat adjustment
with OS endpoint, (C) Z-score normalization with RFS endpoint, (D) ComBat adjustment with RFS endpoint. Genes are presented in rows and samples
are illustrated in columns. Color legend of data source for Figure 4A and Figure 4B: yellow: Vijver, blue: GSE1992, pink: GSE1456, red: GSE3143, brown:
GSE4335. Color legend of data source for Figure 4C and Figure 4D: yellow: GSE2034, blue: GSE4922, pink: GSE1456, red: GSE2990, brown: Vijver, black:
GSE1992, green: GSE4335.
doi:10.1371/journal.pone.0007431.g004
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to the robustness of the gene signatures rather than to the
prediction accuracy measured in cross-validation (compare for
instance to the prediction accuracies of GSE4355 to ComBat- or Z-
score-Merged in Figure 5A). Our results are in agreement with Van
Vliet and colleagues’ findings [7].
Regarding the two performance measures used, it is noteworthy
that HR was not always directly related to the prediction accuracy
expressed as AUC [33]. For example, the gene signature derived
from GSE1992 showed a prediction accuracy of 0.68 with an HR
of 3.06 in one iteration of CV, and a prediction accuracy of 0.63
with an HR of 3.05 in another iteration.
Validation on independent data sets. To assess the
reproducibility of the gene signatures’ performance derived from
the merged data sets, the prediction accuracy was evaluated in a
leave-one-data set-out manner (section Bias Estimation). In each
step, one complete source data set was set aside as testing set while
the predictor was built from the merged remaining sets. In parallel,
we carried out pair-wise tests, using one source data set as training
and another one as testing set. Table 2, Table 3 and Table S1 to
S6 summarize the results of these evaluations with respect to the
two clinical endpoints, OS and RFS.
In this test, merging data sets improved overall survival
prediction and risk association. This interpretation is based on
the fact that for a given testing set, the predictor built from the
merged training set outperformed on average 3 out of 4 predictors
built from the individual sets. With respect to OS, the survival
prediction based on Z-score normalization was higher than the
prognosis accuracy obtained with ComBat. A partial improvement
of the association of the 100-gene signatures with OS (measured by
HR) by merging data sets can also be observed in Table S1 and
Table S2. In this analysis, ComBat outperformed Z-score
normalization.
The partial improvement of survival prediction and risk
association that were observed for OS endpoint were also obtained
with respect to RFS. Between the merged data sets, Z-score
normalization provided higher results than ComBat even though
the difference is not significant (see supplementary information file,
Table S3 to S6).
Overlap between gene signatures
Previous reports pointed out limited overlap between gene
signatures (see discussion in [34,35]). We were wondering whether
this observation could be confirmed by our experiments, and
therefore went on to compare the different gene signatures
obtained in the previous tests to each other. Unsurprisingly, the
top 100-ranked genes generated from different single data sets had
no or poor overlap with each other and with the merged data sets
(data not shown). Reportedly strong prognostic markers like ESR1
and GATA3 were not systematically selected from all data sets.
For example, ESR1 and GATA3 were in the gene signature
generated from GSE4335 but not in the gene signatures derived
from GSE1456 or GSE1992.
The genes selected from the merged data sets based on RFS
were matched to the 70-gene signature published by Vijver et al.
2002 [36]. Note that the 70-gene signature mapped to only 57
genes (CleanEx release of the 3rd September 2007). Only eight of
these genes (C16orf61, CENPA, DTL, MELK, NDC80, NU-
SAP1, ORC6L, PRC1) were also found in the gene-signature
derived from the merged data sets adjusted by ComBat. Even
fewer (four) common genes (CENPA, HRASLS, PECI, PRC1)
were found in the merged data set normalized by Z-score
normalization. This small overlap is in agreement with reported
observations on breast cancer gene signatures. It is furthermore
expected from theory and simulations [35,37].
Factors limiting the success of data merging
To find out why data merging did not lead to an improvement
of performance, a test series were carried out to optimize the gene
signature size for the selected individual and merged data sets
adjusted by ComBat or Z-score by varying the number of genes
from 1, 5, 10, 20, 50, 150, 200, 500 to 1000. We selected for this
test those individual sets, which had annotations for both clinical
endpoints, OS and RFS. Overall, this analysis confirmed that in
Figure 5. The prediction accuracy of the gene signatures generated from the breast cancer merged and single data sets. The results
present the average of the Area Under the Curve (AUC) over 10-fold cross validation. The error bars represent the standard deviation of AUC over 10
iterations. Figure 5A: GSE3143: 0.66+/20.03, GSE1456: 0.55+/20.04, GSE4335: 0.77+/20.02, GSE1992: 0.70+/20.05, Vijver: 0.75+/20.01, ComBat-
merged: 0.68+/20.03, Zscore-merged: 0.68+/20.01, GSE4335Vijver: 0.73+/20.02. Figure 5B: GSE1456: 0.58+/20.02, GSE1992: 0.67+/20.03, GSE4335:
0.74+/20.03, GSE2990: 0.54+/20.04, GSE4922: 0.55+/20.02, GSE2034: 0.62+/20.02, Vijver: 0.67+/20.01, ComBat-merged: 0.63+/20.01, Zscore-
merged: 0.64+/20.00, GSE4335GSE1992: 0.68+/20.02.
doi:10.1371/journal.pone.0007431.g005
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7431most cases the size of 100 was a near-optimal choice for survival
prediction by a Cox regression model (supplementary information
Figure S1). Based on over-fitting considerations, it was expected
that the merged data sets containing more samples would tolerate
larger gene signatures. However, this conjecture was not (or not
clearly) supported by the results.
Case of the gene CYB5D1
New findings on CYB5D1. On comparing the results
obtained for AUC and HR from the individual data sets with
the signatures of variable size, it was surprising to observe the large
variation in the performance profiles. Most strikingly, with the
data set GSE4335, the best performance was obtained with a
signature consisting of a single gene. With an AUC value of 0.8 for
OS prediction, this was the overall best performance registered in
this study. It has to be remembered in this context that the
performance was measured in cross-validation. It was thus not
clear whether in the case of a single-gene signature the same gene
or different genes were selected in each fold of cross-validation. In
principle, the prediction accuracy could reflect the average
performance of different genes selected in successive iterations.
Looking at the results after each fold of cross-validation, we
noticed that the gene CYB5D1 (cytochrome b5 domain containing
1) was selected in 95% of the cases. The Cox coefficients obtained
for this gene were consistently negative, indicating a beneficial
effect on survival. With respect to RFS endpoint, this gene was
Figure 6. HR of the gene signatures derived from the merged and single breast cancer data sets. Figure 6A: GSE3143: HR=2.17,
CI=1.67–2.82, GSE1456: HR=1.43 CI=0.77–2.64, GSE1992: HR=3.42 CI=1.90–6.14, GSE4335: HR=4.06 CI=2.60–6.34, Vijver: HR=5.57 CI=4.44–6.99,
ComBat-merged OS: HR=3.84, CI=3.17–4.65, Zscore-merged OS: HR=3.31, CI=2.55–4.30, GSE4335Vijver: HR=4.80, CI=4.19–5.50. Figure 6B:
GSE1456: HR=1.48, CI=0.68–3.20, GSE1992: HR=3.01, CI=2.24–4.05, GSE4335: HR=3.59, CI=2.58–5.00, GSE2990: HR=1.58, CI=0.75–3.32, GSE4922:
HR=1.38, CI=0.93–2.05, GSE2034: HR=1.95, CI=1.47–2.58, Vijver: HR=3.30, CI=3.05–3.57, ComBat-merged RFS: HR=2.09, CI=1.83–2.39, Zscore-
merged RFS: HR=2.09, CI=1.83–2.39, GSE4335GSE1992: HR=3.72, CI=2.91–4.75.
doi:10.1371/journal.pone.0007431.g006
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gene signature was found to be 0.73.
We were not the first to find that a 1-gene signature had an
equally good or stronger prognostic power than a gene signatures
with a higher number of genes. Haibe-Kains and colleagues [3]
previously found the proliferation gene AURKA to be a strong
survival predictor at least as good as any composite gene predictor
based on advanced machine-learning techniques.
The excellent performance of one gene in survival prediction
immediately raises the question whether this gene was included in
all studies. If this were not the case, then the gene would not be
present in the merged data set, which could explain the rather
disappointing prediction accuracy figures obtained after merging.
Indeed, this gene was absent in a number of data sets. In one other
data set where it was present, its performance as a single-gene
signature in risk prediction was consistently high (GSE1992,
AUC=0.68, HR=3.24, P-value=0.008, CI=1.36–7.72). The
influence of this gene could also explain the good performance
obtained after merging selectively the sets GSE4335 and
GSE1992 (see above). A possible reason that adding the Vijver
data set did not improve the prediction accuracy might be due to
the fact that this gene was absent in the original Vijver study. As
expected, the Cox coefficient of this gene was negative for all data
sets in which it was present, meaning low risk associated with high
expression levels. The case of CYB5D1 suggests that the absence
of key risk or survival genes from some microarray platforms
may in general be a major limiting factor in data merging,
demonstrated here on the specific example of survival prediction
for breast cancer patients.
Known findings on CYB5D1
The fullname of CYB5D1is ‘‘cytochrome b5 domaincontaining
1’’. It is noteworthy that the gene is absent from the well known
prognostic gene signatures published by van de Vijver et al. [36]
and Wang et al. [38] even though this is not surprising as the gene
was not present on the gene expression profiling platform used in
these studies. We wanted to know whether this gene was previously
found as a survival gene in similar studies. An initial search with
gene symbol CYB5D1 was unsuccessful. However, using UniGene
ID Hs.27475 [27], we found a few earlier cancer studies where this
gene was selected as a differentially regulated gene.
Jenssen and colleagues [39] found Hs.27475 associated to breast
cancer survival. In their study, they used the Sorlie data set [40], a
subset of GSE4335 analyzed in this work. Using a Log-rank test
applied to discretized survival data, they identified 95 genes
positively or negatively correlated with survival (P-valuev0.05,
with Bonferroni correction [32]). In their gene list ranked by P-
value, Hs.27475 appeared at rank 11 (rank 6 if positively
correlated genes are considered only) with P-value 9.4e-10.
The expression of Hs.27475 was also found to be positively
correlated (Pearson correlation of 0.58) with the expression of
Estrogen Receptor 1 (ESR1) [41]. In this study performed by
Mackay et al., paired biopsies from 34 ER positive breast cancer
patients, taken before and after treatment were analyzed with
cDNA microarrays. The patients were treated with aromatase
inhibitors like anastrozole and letrozole that are suppressants of
estrogen synthesis. It needs to be pointed out that the main goal of
this study was to identify estrogen target genes, not genes that
correlate with ESR1 expression. In this respect, Hs.27475 was not
Table 2. Cross-data set performance of the breast cancer predictors trained on the individual and combined data sets (by ComBat)
with respect to OS.
GSE1456 GSE1992 GSE4335 Vijver GSE3143 Merged-ComBat 
GSE1456 NA 0.67 0.70 0.77 0.71 0.75
GSE1992 0.62 NA 0.57 0.56 0.61 0.62
GSE4335 0.62 0.68 NA 0.73 0.66 0.70
Vijver 0.77 0.73 0.70 NA 0.68 0.77
GSE3143 0.67 0.47 0.54 0.56 NA 0.62
Significant AUC (w0.6) are shown in bold. The training sets are listed in the column header and the testing sets are indicated in the row header of the table.
 indicates that the predictor was trained from all data sets except the testing set. NA stands for Not Available.
doi:10.1371/journal.pone.0007431.t002
Table 3. Cross-data set performance of the breast cancer predictors trained on the individual and combined data sets (normalized
by Z-score normalization) with respect to OS.
GSE1456 GSE1992 GSE4335 Vijver GSE3143 Merged-zscore 
GSE1456 NA 0.64 0.68 0.76 0.68 0.77
GSE1992 0.56 NA 0.59 0.56 0.63 0.60
GSE4335 0.65 0.66 NA 0.69 0.76 0.70
Vijver 0.75 0.72 0.69 NA 0.71 0.75
GSE3143 0.62 0.51 0.50 0.56 NA 0.60
Significant AUC (w0.6) are shown in bold. The training sets are listed in the column header and the testing sets are indicated in the row header of the table. Merged-
zscore refers to the merged data set composed of the individual data set normalized separately by Z-score normalization.
 indicates that the predictor was trained from all data sets except the testing set. NA stands for Not Available.
doi:10.1371/journal.pone.0007431.t003
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regulation genes found by the analysis of the paired samples.
Hs.27475 was noticed to be about two-fold downregulated in
two other types of cancer, primary colon and primary rectal
carcinoma [42]. In this study, the colon data set was composed of
73 tumors of locally advanced colon carcinomas that were profiled
on oligonucleotide microarrays containing 21543 features. The
rectal data set was taken from a previous study [43] in which 29
rectal carcinoma and 20 normal mucosa samples were analyzed
on a oligonucleotide microarray containing 22,231 features.
Hs.27475 was down-regulated at P-valuev0.0001 in the two
data sets. Note further that this gene was among 490 common
genes found to be deregulated (up or down) in both tumor types.
The down-regulation of CYB5D1 colon cancer is consistent with
its role of a survival gene in breast cancer.
It may also be worthwhile to mention that CYB5D1 belongs to
the same protein family as Progesterone receptor membrane
component 1 (PGRMC1), a well known player in the breast
cancer field [44]. However, this gene shows opposite behaviour in
most respects. It is over-expressed in cancer, particularly in ER
negative breast cancer, and correlates with poor prognosis as it
makes cells resistant to chemotherapeutic drugs [44]. However,
the findings related to PGRMC1 may help to elucidate the
molecular mechanisms through which CYB5D1 reduced the
malignant potency of breast cancer cells. PGRMC1 binds to and
presumably regulates the enzymes of the P450 family, whose
activity may interfere with drug resistance or intracellular
signalling pathways [44].
In summary, the findings summarized above indicate that
CYB5D1 is an important but currently not well known survival
gene in breast cancer with potential diagnostic and therapeutic
value.
Survival analysis of patients information and tumor
characteristics
Previous breast cancer studies attempted to improve survival
prediction by integrating clinical variables with microarray gene
expression data [15,36,38,45–48]. In these studies, the clinical
variables and the gene signatures were fitted simultaneously in a
multivariate Cox regression model to determine their adjusted
HR. The purpose was to find out if the expression data derived
gene signatures had true added value with regard to clinical risk
factors or whether the association of the gene signature was
mediated entirely by clinical variables.
Five patients characteristics and clinicopathological parameters
such as age, tumor grade, tumor size, estrogen receptor (ER) status
and lymph node status that were available in five data sets were
used here (Table 4). We also carried out tests in these settings
with the specific goal to find out whether the gene signatures
derived from the merged data sets had more clinical variable-
independent predictive power than the gene signatures derived
from the individual sets. Details of the protocol are described
under Methods section.
As Table 5 and Table 6 show, merging data sets improves the
association of the gene signatures with OS compared to only one
data set (out of three) and increases the HR of the gene signatures
with respect to RFS for four out of five data sets. These results
show that integration of data sets improved partially the adjusted
HR of the gene signatures. On the other hand, the adjusted HR
did not improve after merging for tumor grade or tumor size.
Methods
Statistical analysis was performed using R [49], version 2.5.1
and BioConductor [50], release 2.0.
Data sets
The data sets used in this study were pre-normalized in various
ways by the authors of the original studies (Table 1). The gene
expression data were imported via the CleanEx database [29]
which simultaneously provides a mapping of microarray features
to gene names. Note that throughout this document, clinical
endpoints, clinical outcomes, or prediction outcomes refer to OS
and/or RFS.
Time to OS is defined as the time between surgery and death
from breast cancer or the last date of follow-up. Time to RFS is
defined as the time between surgery and the first recurrence of
local, regional or distant-metastatic breast tumor or the last date of
follow-up. If OS or RFS time refers to death or recurrence of
disease, the corresponding samples have a censoring status of 1
(event happened) or 0 otherwise.
We limited the analysis to 10 years of follow-up as the majority
of breast cancer patients had a follow-up of maximum 10 years. All
patients having an overall survival or relapse free survival greater
than 10 years were censored and their respective clinical endpoint
was set to 10 years. All patients in GSE4335 deceased from any
other cause than breast cancer were also censored. Fibroadenoma
or normal breast samples were discarded from the study
(GSE4335, GSE1992). Replicate samples in GSE1992 were
eliminated from the study, too. Note that throughout this
document, GSE1456 refers to the merged data set of GSE1456A
and GSE1456B, GSE4922 to the merged data set of GSE4922A
and GSE4922B, respectively. GSE4335 and Vijver are data sets
from clinical trials.
Table 4. Clinical data of the single and merged breast cancer data sets.
Data set Grade1 Grade2 Grade3 Size1 Size2 Size3 Size4 Age(ƒ50y) Age(w50y) ER+ ER- LN+ LN-
GSE4335 11 49 53 6 13 62 32 34 81 82 31 79 34
GSE1992 12 43 63 30 59 21 11 55 67 70 50 71 50
Vijver 75 101 119 155 140 0 0 264 31 226 69 144 151
GSE2990 64 48 55 103 80 4 0 62 125 147 34 30 153
GSE4922 68 126 55 165 84 0 0 54 195 211 34 81 159
Merged OS 98 193 235 191 212 83 43 353 179 378 150 294 235
Merged RFS 193 339 325 340 382 114 43 635 247 661 212 550 327
The number of patients by clinical variables is presented in each cell of the table. ER+=Estrogen Receptor positive, ER-=Estrogen Receptor negative, LN+=Lymph
Node positive, LN-=Lymph Node negative.
doi:10.1371/journal.pone.0007431.t004
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Global mean normalization was used for GSE1456A&B and
GSE4922A&B. The probe set values were natural log-transformed
followed by an adjustment of the mean intensity to a target signal
value of log 500. The pre-normalization of Vijver data set was
performed on an array-by-array basis. Raw intensities from each
channel (red or green) were divided by the mean intensity (in
linear scale) of the corresponding channel. The other data sets
were pre-normalized as described in the legend to Table 1.
Grade, size, ER and lymph node status are discrete variables
(Table 4). Grade was originally coded as three types (according to
the Tumor-Node-Metastasis (TNM) classification [51]): type 1
(well-differentiated), type 2 (intermediate) and type 3 (poorly-
differentiated). ER had binary value, 0 for ER- and 1 for ER+.
Lymph node status had also binary value, 0 for negative node and
1 for any number of positive nodes (1 or more). Tumor size was
classified into T1, T2, T3 or T4 in the original studies (according
to the TNM classification) except for GSE2990 and GSE4922. In
these two data sets, tumor diameter was available and converted
into discrete classes according to TNM classification. Originally,
age had continuous values (in years). Its value was transformed
into a binary category: 0 if age is less or equal to 50 years and 1
otherwise.
Samples containing missing values were discarded in the analyses
using clinical variables. Note that the five variables, grade, size, ER,
lymph node status and age were only available in three data sets
(GSE4335, GSE1992 and Vijver) with overall survival endpoint
(total of 532 samples) and in five data sets (GSE4335, GSE1992,
Vijver, GSE2990 and GSE4922) with relapse free survival outcome
(total of 882 samples).
Pre-processing data
K Nearest Neighbor (KNN) imputation [52] was used to impute
missing expression values in the source data sets, using the function
impute.knn of the R package impute with default parameters
(including k=10). The probes/probe sets were mapped to Genew
gene symbols [53] via CleanEx [29] (release of the 3rd September
2007). When multiple probes/probe sets were mapped to the same
gene, the expressions of multiple probes/probe sets were averaged
(after KNN imputation).
Data Integration methods
Z-score normalization (scale function in stats R package) and
ComBat [25] were used to adjust the systematic bias of data sets
generated by different platforms. Z-score normalization was applied
first to the samples and then, to the genes. Z-score normalization
was applied after merging if not specified otherwise.
Feature Selection
Genes were selected based on univariate Cox P-value ranking
using the coxph function in survival R package. In this feature
selection method, the genes were ranked based on their likelihood
ratio P-value and the 100 genes with the smallest P-values were
retained as the gene signature if not specified otherwise.
The genes were selected either in Cross Validation (CV) mode or
in a training set independent from the testing set. In case of CV, the
expression values of the genes were fitted individually to survival
data,andrankedby P-valuesineachfold.Then,thetop100-ranked
genes were selected for the gene signature. In case of independent
training/testing sets, the genes were selected from the training set.
Table 5. Adjusted HR of the breast cancer gene signatures and clinical variables with OS endpoint.
Data set 100-gene signature Grade Size ER LN Age
GSE4335 2.19 (1.20–3.99) 2.01 (1.80–2.25) 1.31 (1.21–1.42) 0.53 (0.45–0.62) 0.94 (0.92–0.97) 0.68 (0.59–0.76)
GSE4335 1-gene signature 5.28 (2.44–11.41) 2.47 (2.28–2.67) 1.08 (0.96–1.21) 0.41 (0.37–0.45) 0.90 (0.87–0.94) 0.67(0.61–0.76)
GSE1992 1.23 (0.8–1.89) 3.26 (2.96–3.59) 1.95 (1.84–2.07) 0.29 (0.27–0.31) 3.92 (3.36–4.57) 1.20 (0.91–1.58)
Vijver 3.15 (2.15–4.61) 1.48 (1.34–1.63) 1.53 (1.50–1.56) 0.67 (0.63–0.71) 0.97 (0.93–1.01) 1.17 (1.02–1.22)
ComBat merged OS 1.39(0.8–2.42) 2.24 (1.92–2.61) 1.94 (1.90–1.98) 0.51 (0.43–0.61) 1.24 (1.19–1.29) 1.07 (1.00–1.14)
Z-score merged OS 1.36 (1.10–1.68) 1.31 (1.21–1.42) 1.52 (1.49–1.55) 0.84 (0.78–0.91) 1.47 (1.39–1.56) 1.03 (1.00–1.06)
The CI (in parentheses) presents the CI of the geometric mean calculated in 10 iterations of 10 fold cross validation. LN refers to lymph node status and ER to estrogen
receptor, respectively.
doi:10.1371/journal.pone.0007431.t005
Table 6. Adjusted HR of the breast cancer gene signatures and clinical variables with RFS endpoint.
Data set 100-gene signature Grade Size ER LN Age
GSE2990 0.87(0.47–1.61) 1.12(1.08–1.17) 2.79(2.68–2.90) 0.86(0.77–0.97) 0.79(0.73–0.85) 0.59(0.54–0.65)
GSE4922 0.95(0.51–1.76) 1.45(1.34–1.57) 2.12(1.96–2.29) 1.39(1.19–1.62) 1.44(1.38–1.50) 0.91(0.88–0.94)
GSE4335 2.19(1.24–3.87) 1.79(1.51–2.13) 1.61(1.52–1.71) 0.70(0.57–0.86) 0.98(0.92–1.04) 0.63(0.57–0.68)
GSE43351-gene signature 2.49(1.54–4.02) 1.51(1.37–1.66) 2.11(1.88–2.37) 0.57(0.45–0.72) 1.00(0.92–1.08) 0.62(0.56–0.71)
GSE1992 1.78(1.04–3.05) 2.38(2.12–2.67) 1.69(1.62–1.76) 0.53(0.42–0.68) 8.10(7.21–9.10) 0.85(0.76–0.95)
Vijver 2.62(2.17–3.17) 1.20(1.13–1.27) 1.38(1.33–1.44) 1.07(0.99–1.16) 0.91(0.87–0.95) 1.02(0.95–1.13)
ComBat merged RFS 1.33(1.04–1.70) 1.33(1.25–1.41) 1.43(1.4–1.46) 0.79(0.77–0.81) 1.29(1.24–1.34) 0.73(0.69–0.77)
Z-score merged RFS 2.56(1.51–4.33) 1.27(1.09–1.48) 1.57(1.42–1.73) 0.85(0.73–0.99) 1.45(1.34–1.57) 0.99 (0.97–1.01)
The CI (in parentheses) presents the CI of the geometric mean calculated in 10 iterations of 10 fold cross validation. LN refers to lymph node status and ER to estrogen
receptor, respectively.
doi:10.1371/journal.pone.0007431.t006
Survival Prediction & Merging
PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7431Principal Component Analysis
Principal Component Analysis (PCA) was applied using the
prcomp function in R stats package with default parameters except
that the center parameter was set to FALSE.
Clustering
The gene expression data were clustered using complete-linkage
agglomerative hierarchical clustering based on the Euclidean
distance (heatmap.2 function in R gplots package).
Prediction Method
Patients risk score was calculated as the linear combination of
the Cox coefficients estimated from the training set and the
corresponding gene expression values (Equation 1).
lp x,b ðÞ ~
X G
i
bixi ð1Þ
Performance Estimation
Bias Estimation. The survival predictors were assessed by
the following methods:
1. 10-fold cross validation (10fCV) nested in 10 iterations.
2. Leave one data set out: all data sets except one were merged
together to form the training set and the left-out set was used as
the testing set. This process was iterated until all data sets were
used in the training and testing sets.
In 10fCV, the data integration (ComBat or Z-score) was applied
separately to the training and testing sets in each cross-validation
fold. Note that the training and testing sets were generated by
merging and subsequent random splitting. Thus both contained
the samples from different sources. Since ComBat needs the
source- (batch)-identifiers as input, those identifiers had to be
carried through the cross-validation protocol. In case of leave-one-
data set-out, Z-score normalization was applied to each data set
separately prior to merging.
Prediction Estimation. Time-dependent ROC curves [54]
were used to evaluate the prediction accuracy at maximum time
point for each data set using the nearest neighbor estimator
(survivalROC R package). In 10fCV, the accuracy of the
prediction of patients survival time (OS or RFS) was represented
by the mean and standard deviation (SD).
The association of the gene signatures to survival (OS or RFS)
was also measured by a hazard ratio (HR). To this end, the
patients of the testing set had to be stratified into predicted high-
and low-risk groups. In both 10fCV and independent validation, a
testing sample score was considered as high risk, if it was higher
than the median score of the training sample and low risk
otherwise.
In case of 10fCV, HR was averaged by geometric mean
(Equation 2). The 95% CI of the HR over 10 iterations of 10-fold
cross validation corresponds to the CI of the geometric mean.
GM~ P
n
i~1
hri
   n
~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hr1:hr2 ...hrn
n p
ð2Þ
where GM refers to Geometric Mean and hr is a vector of n
elements.
95% CI~explog GM ðÞ +1:96:SE log hr ðÞ ðÞ ð3Þ
where SE stands for Standard Error.
The gene-signature-based risk scores were also evaluated in the
context of clinical parameters, using the same type of cross-
validation protocol. The binary risk scores computed for each
testing set sample (low/high-risk group as described above)
together with the five clinical parameters listed in Table 4 were
adjusted to survival data by multivariate Cox regression analysis
(using coxph function in survival R package). This fitting
procedure returned a hazard ratio for each input parameter.
Again, the results of 10fCV were summarized by the geometric
mean.
Discussion
The survival prediction accuracy and prognosis of clinical risk
were neither increased nor decreased significantly by merging data
sets. This is explained at least in part by the fact that important risk-
associated genes were not present in all data sets. Consequently, the
heterogeneity of the data sets generated from different laboratories
and with different microarray technologies, was not the only,
perhaps even not the major limiting factor for improving prediction
accuracy by increasing sample size. Substantial variation of time to
death or relapse among breast cancer patients and the heteroge-
neity of breast cancer disease are other constraining factors that
nevertheless need to be considered. Moreover, the heterogeneity of
patients cohorts in terms of age, lymph node status, tumor grade,
tumor size and ER status might negatively affect the accuracy of
survival prediction after merging. It is known, for example, that the
ER+ patients have good prognosis (long survival) and ER- negative
patients have poor prognosis (short survival) in the first five years
after the diagnosis or surgery.
Despite the caveats mentioned above, the results show that
selectively merging those data sets which give rise to accurate
predictors if used alone, can improve the performance. Moreover,
our results confirm that the predictors based on large merged data
sets are more robust, i.e. their worst performance observed in
multiple iterations of cross-validation tends to be substantially
better compared to the worst performance of the gene signatures
based on the single data sets. This may be viewed as an advantage
by itself. In general, the prediction accuracy of the gene signatures
derived from the merged data sets remained consistent and
reproducible across independent studies. Prediction accuracies
measured in cross-validation were extensible to independent
testing sets.
The systematic evaluation of predictors built from the single and
merged gene expression data sets also led us to the surprising
observation that a single-gene signature consisting of CYB5D1 had
the highest prediction accuracy and strongest patients risk
association in breast cancer, surpassing all gene signatures with
different gene size evaluated in this study. CYB5D1 was already
mentioned in breast and other types of cancer studies (see results
section). The protein encoded by this gene belongs to the same
family as Hpr6 (also called PGRMC1) which was found to increase
the resistance of tumor cells to DNA-damaging agents. However,
the CYB5D1 negatively correlates with a patients risk (found in
this study), suggesting that it has the opposite effect. It seems
nevertheless plausible that the expression of this gene also
interferes with drug metabolism. This hypothesis is compatible
with the fact that the strongest predictive power of this gene was
seen in a data set primarily composed of patients which received
adjuvant chemotherapy before surgery.
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paradigm that composite gene signatures perform better than one-
gene signatures in cancer disease outcome prognosis.
Supporting Information
Table S1 Cross-data set performance of breast cancer predictors
trained on the individual and combined data sets (adjusted by
ComBat) with respect to OS. Significant HR (p,0.05) are shown
in bold. The training sets are listed in the column header and the
testing sets are indicated in the row header of the table. * indicates
that the predictor was trained from all data sets except the testing
set. NA stands for Not Available.
Found at: doi:10.1371/journal.pone.0007431.s001 (0.04 MB
PDF)
Table S2 Cross-data set performance of breast cancer predictors
trained on the individual and combined data sets (normalized by
Z-score normalization) with respect to OS. Significant HR
(p,0.05) are shown in bold. The training sets are listed in the
column header and the testing sets are indicated in the row header
of the table. Merged-zscore refers to the merged data set combined
from the individual data sets, each normalized separately by Z-
score normalization. * indicates that the predictor was trained
from all data sets except the testing set. NA stands for Not
Available.
Found at: doi:10.1371/journal.pone.0007431.s002 (0.04 MB
PDF)
Table S3 Cross-data set performance of breast cancer predictors
trained on the individual and combined data sets (adjusted by
ComBat) with respect to RFS. Significant AUC (.0.60) are shown
in bold. The training sets are listed in the column header and the
testing sets are indicated in the row header of the table. * indicates
that the predictor was trained from all data sets except the testing
set. NA stands for Not Available.
Found at: doi:10.1371/journal.pone.0007431.s003 (0.04 MB
PDF)
Table S4 Cross-data set performance of breast cancer predictors
trained on the individual and combined data sets (normalized by
Z-score normalization) with respect to RFS. Significant AUC
(.0.60) are shown in bold. The training sets are listed in the
column header and the testing sets are indicated in the row header
of the table. Merged-zscore refers to the data set merged from the
individual data set, each normalized separately by Z-score
normalization. * indicates that the predictor was trained from all
data sets except the testing set. NA stands for Not Available.
Found at: doi:10.1371/journal.pone.0007431.s004 (0.04 MB
PDF)
Table S5 HR of breast cancer predictors trained on the
individual and combined data sets (adjusted by ComBat) with
respect to RFS. Significant HR (p,0.05) are shown in bold. The
training sets are listed in the column header and the testing sets are
indicated in the row header of the table. * indicates that the
predictor was trained from all data sets except the testing set. NA
stands for Not Available.
Found at: doi:10.1371/journal.pone.0007431.s005 (0.04 MB
PDF)
Table S6 HR of breast cancer predictors trained on the
individual and combined data sets (normalized by Z-score
normalization) with respect to RFS. Significant HR (p,0.05) are
shown in bold. The training sets are listed in the column header
and the testing sets are indicated in the row header of the table.
Merged-zscore refers to the data set merged from the individual
data set, each normalized separately by Z-score normalization. *
indicates that the predictor was trained from all data sets except
the testing set. NA stands for Not Available.
Found at: doi:10.1371/journal.pone.0007431.s006 (0.04 MB
PDF)
Figure S1 Prediction performance of the breast cancer gene
signatures as a function of the number of genes. Gene nb refers to
the number of genes.
Found at: doi:10.1371/journal.pone.0007431.s007 (1.12 MB TIF)
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